| 0 (0%) | 01-19 18:54 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 104.82 | 1-year : | 112.75 |
| Resists | First : | 89.74 | Second : | 96.54 |
| Pivot price | 84.08 |
|||
| Supports | First : | 78.75 | Second : | 65.52 |
| MAs | MA(5) : | 82.71  |
MA(20) : | 84.9 |
| MA(100) : | 76.71 |
MA(250) : | 59.44 |
|
| MACD | MACD : | -1.3 |
Signal : | -1 |
| %K %D | K(14,3) : | 47.5 |
D(3) : | 41.4 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 96.54 | Low : | 33.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PTGX ] has closed above bottom band by 32.3%. Bollinger Bands are 1.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 84.6 - 85.06 | 85.06 - 85.44 |
| Low: | 80.36 - 80.93 | 80.93 - 81.4 |
| Close: | 81.13 - 82 | 82 - 82.73 |
Thu, 15 Jan 2026
Protagonist Therapeutics (PTGX) Valuation Check After Strong Multi Year Return And Recent Share Price Pullback - simplywall.st
Wed, 14 Jan 2026
SG Americas Securities LLC Grows Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wed, 14 Jan 2026
Does Rusfertide’s FDA NDA Submission Redefine The Bull Case For Protagonist Therapeutics (PTGX)? - simplywall.st
Tue, 13 Jan 2026
Trading the Move, Not the Narrative: (PTGX) Edition - Stock Traders Daily
Wed, 07 Jan 2026
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? - Yahoo Finance
Tue, 06 Jan 2026
Protagonist (PTGX) Stock Pre-Market (-6.4%): NDA Submission For Rusfertide Triggers Sell-The-News - Trefis
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 63 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 115.9 (%) |
| Shares Short | 6,540 (K) |
| Shares Short P.Month | 5,580 (K) |
| EPS | 0.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.34 |
| Profit Margin | 21.9 % |
| Operating Margin | -985.2 % |
| Return on Assets (ttm) | 1.8 % |
| Return on Equity (ttm) | 7.8 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | 3.34 |
| Sales Per Share | 3.34 |
| EBITDA (p.s.) | 0.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 65 (M) |
| Levered Free Cash Flow | 53 (M) |
| PE Ratio | 124.22 |
| PEG Ratio | 0 |
| Price to Book value | 7.92 |
| Price to Sales | 24.5 |
| Price to Cash Flow | 78.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|